Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Basarir H. Poor, multidimensionally speaking: evidence from South Africa. J Afr Econ. 2011 Jun 1;20(3):463-504. doi: 10.1093/jae/ejr001